institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 5 days ago • loading... • Updated 5 days ago

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Summary by Star Local

Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy

36 Articles

36 Articles

All

Left

1

Center

14

Right

1

+34 Reposted by 34 other sources

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy

5 days ago

Read Full Article

Keros Therapeutics Announces $375 Million Capital Return Plan Following Strategic Review

Keros Therapeutics plans to return $375 million to stockholders after a strategic review, while advancing its drug development efforts.

5 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources36

Leaning Left1Leaning Right1Center14Last Updated4 days agoBias Distribution

88% Center

Bias Distribution

88% of the sources are Center

88% Center

+9

Untracked bias

+11

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States 5 days ago on Monday, June 9, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics